To evaluate the association of androgen deprivation therapy (ADT) with cognitive dysfunction.
INTRODUCTION AND OBJECTIVES:
There is limited epidemiological evidence for the association between androgen deprivation therapy (ADT) and the risk of incident dementia, yet several studies show no such association. Consequently, we aim to assess if receipt of ADT increases the risk of dementia among men with localized and locally advanced prostate cancer and if it does so in a dose-dependent manner.
METHODS: We conducted a retrospective cohort study using Surveillance, Epidemiology, and End Results (SEER)-Medicare linked data among 100,414 men aged 66 years and older who were diagnosed with localized and locally advanced prostate cancer (cT1 -cT4) between January 1992 and December 2009 and followed until administrative end of follow-up at 36 months or death. Men were excluded if they had a prior history of stroke, dementia or use of psychiatric services reported in Medicare claims. Propensity weighted competing risk Cox regression models were utilized to estimate hazard ratios (HR) and 95% confidence intervals for the risk of Alzheimer's, allcause dementia, and use of psychiatric services following different doses of pharmacologic ADT (0, 1-6, and !7 months).
RESULTS: Of the 100,414 men with prostate cancer (median age 73 [IQR: 69-77] years; 84% white, 10% black), 38% (n[ 37,911) received ADT within 6 months of diagnosis. Receipt of any pharmacologic ADT was associated with 22% increased risk of all-cause dementia (HR 1.22, 95% CI 1.12-1.33, p<0.001), 29% increased risk of Alzheimer's (HR 1.29, 95% CI 1.16-1.43, p<0.001), and 15% increased risk of psychiatric services use (HR 1.15, 95% CI 1.04-1.28, p[0.008). Additionally, ADT showed a dose-response relationship for the duration of !7 months with all-cause dementia and Alzheimer's, where there was an increased risk of 30% and 41%, respectively, in comparison to no ADT. A dose-response relationship was not seen for ADT and use of psychiatric services (ptrend[0.07). CONCLUSIONS: Our study supports an association between pharmacologic ADT and increased risk of developing all-cause dementia, Alzheimer's, and use of psychiatric services in men with localized and locally advanced prostate cancer. Longer duration of ADT !7 months corresponded with greater risk of these events. These data provide additional evidence supporting an effect of ADT on cognitive health. 
